002294 信立泰
已收盘 12-23 15:00:00
资讯
新帖
简况
12月13日信立泰发生1笔大宗交易 成交金额5.9亿元
证券之星 · 12-13
12月13日信立泰发生1笔大宗交易 成交金额5.9亿元
信立泰12月11日现1笔大宗交易 成交金额992.25万元
新浪证券-红岸工作室 · 12-11
信立泰12月11日现1笔大宗交易 成交金额992.25万元
12月11日信立泰现992.25万元大宗交易
证券之星 · 12-11
12月11日信立泰现992.25万元大宗交易
信立泰(002294)12月2日主力资金净买入742.04万元
证券之星 · 12-03
信立泰(002294)12月2日主力资金净买入742.04万元
信立泰(002294.SZ):阿利沙坦酯氨氯地平片、苯甲酸福格列汀片新纳入国家医保目录
智通财经 · 11-28
信立泰(002294.SZ):阿利沙坦酯氨氯地平片、苯甲酸福格列汀片新纳入国家医保目录
信立泰11月27日现1笔大宗交易 成交金额365.64万元
新浪证券-红岸工作室 · 11-27
信立泰11月27日现1笔大宗交易 成交金额365.64万元
11月27日信立泰现365.64万元大宗交易
证券之星 · 11-27
11月27日信立泰现365.64万元大宗交易
A股减肥药板块盘初活跃,昊帆生物涨超10%,诺泰生物、华森制药涨超4%,恒瑞医药、信立泰、百花医药等跟涨。
美港电讯 · 11-27
A股减肥药板块盘初活跃,昊帆生物涨超10%,诺泰生物、华森制药涨超4%,恒瑞医药、信立泰、百花医药等跟涨。
信立泰(002294)11月26日主力资金净买入4423.40万元
证券之星 · 11-27
信立泰(002294)11月26日主力资金净买入4423.40万元
11月25日信立泰发生3笔大宗交易 成交金额1335.23万元
证券之星 · 11-25
11月25日信立泰发生3笔大宗交易 成交金额1335.23万元
信立泰(002294.SZ)拟3000万元增资普瑞基准 提升研发效率
智通财经 · 11-22
信立泰(002294.SZ)拟3000万元增资普瑞基准 提升研发效率
信立泰:仿制药龙头押注创新药
微博财经-财道工作室 · 11-21
信立泰:仿制药龙头押注创新药
信立泰(002294)11月19日主力资金净卖出2318.94万元
证券之星 · 11-20
信立泰(002294)11月19日主力资金净卖出2318.94万元
信立泰(002294)11月5日主力资金净卖出1317.69万元
证券之星 · 11-06
信立泰(002294)11月5日主力资金净卖出1317.69万元
信立泰:10月29日接受机构调研,交银基金、国泰君安等多家机构参与
证券之星 · 10-30
信立泰:10月29日接受机构调研,交银基金、国泰君安等多家机构参与
华安证券:给予信立泰买入评级
证券之星 · 10-24
华安证券:给予信立泰买入评级
信立泰(002294)10月23日主力资金净卖出1503.32万元
证券之星 · 10-24
信立泰(002294)10月23日主力资金净卖出1503.32万元
华鑫证券:给予信立泰买入评级
证券之星 · 10-23
华鑫证券:给予信立泰买入评级
信立泰(002294)2024年三季报简析:营收净利润同比双双增长
证券之星 · 10-23
信立泰(002294)2024年三季报简析:营收净利润同比双双增长
信立泰(002294)10月21日主力资金净卖出800.25万元
证券之星 · 10-22
信立泰(002294)10月21日主力资金净卖出800.25万元
加载更多
公司概况
公司名称:
深圳信立泰药业股份有限公司
所属行业:
医药制造业
上市日期:
2009-09-10
主营业务:
深圳信立泰药业股份有限公司主营业务是药品、医疗器械产品的研发、生产、销售。主要产品心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物等。
发行价格:
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":31.75,"timestamp":1734937407000,"preClose":32.8,"halted":0,"volume":6173165,"delay":0,"floatShares":1115000000,"shares":1115000000,"eps":0.5478,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.05,"latestTime":"12-23 15:00:00","open":32.75,"high":32.85,"low":31.63,"amount":198000000,"amplitude":0.0372,"askPrice":31.76,"askSize":29,"bidPrice":31.75,"bidSize":37,"shortable":0,"etf":0,"ttmEps":0.5478,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"adjPreClose":32.8,"symbolType":"stock","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":36.08,"lowLimit":29.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"pbRate":4.25,"roa":"--","roe":"6.23%","epsLYR":0.52,"committee":0.068894,"marketValue":35395000000,"floatMarketCap":35387000000,"peRate":57.959109,"changeRate":-0.032,"turnoverRate":0.0055,"status":1},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2491346572","title":"12月13日信立泰发生1笔大宗交易 成交金额5.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491346572","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491346572?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:51","pubTimestamp":1734079870,"startTime":"0","endTime":"0","summary":"证券之星消息,12月13日信立泰发生大宗交易,交易数据如下:大宗交易成交价格32.65元,相对当日收盘价折价3.89%,成交1807.53万股,成交金额59015.8万元,买方营业部为机构专用,卖方营业部为机构专用。近三个月该股共发生7笔大宗交易,合计成交33.92万手,折价成交7笔。截至2024年12月13日收盘,信立泰报收于33.97元,下跌0.61%,换手率0.49%,成交量5.47万手,成交额1.85亿元。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300029051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","BK0188","BK0196","BK0239","BK0187","002294"],"gpt_icon":0},{"id":"2490835265","title":"信立泰12月11日现1笔大宗交易 成交金额992.25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490835265","media":"新浪证券-红岸工作室","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490835265?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:00","pubTimestamp":1733907600,"startTime":"0","endTime":"0","summary":" 12月11日,信立泰收跌0.91%,收盘价为33.76元,发生1笔大宗交易,合计成交量31.5万股,成交金额992.25万元。 进一步统计,近3个月内该股累计发生6笔大宗交易,合计成交金额为5.37亿元。该股近5个交易日累计上涨0.12%,主力资金合计净流入1875.84万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-12-11/doc-inczarzp3946048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0183","BK0188","BK0187","BK0196","002294","BK0239"],"gpt_icon":0},{"id":"2490338688","title":"12月11日信立泰现992.25万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2490338688","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490338688?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:45","pubTimestamp":1733906752,"startTime":"0","endTime":"0","summary":"证券之星消息,12月11日信立泰发生大宗交易,交易数据如下:大宗交易成交价格31.5元,相对当日收盘价折价6.69%,成交31.5万股,成交金额992.25万元,买方营业部为华泰证券股份有限公司南京江宁苏源大道证券营业部,卖方营业部为海通证券股份有限公司上海黄浦区福州路证券营业部。近三个月该股共发生6笔大宗交易,合计成交15.85万手,折价成交6笔。截至2024年12月11日收盘,信立泰报收于33.76元,下跌0.91%,换手率0.3%,成交量3.35万手,成交额1.13亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121100027279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0188","BK0183","BK0187","BK0196","BK0239","BK0028"],"gpt_icon":0},{"id":"2488939886","title":"信立泰(002294)12月2日主力资金净买入742.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488939886","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488939886?lang=zh_cn&edition=full","pubTime":"2024-12-03 09:22","pubTimestamp":1733188941,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年12月2日收盘,信立泰报收于34.62元,下跌0.52%,换手率0.65%,成交量7.29万手,成交额2.52亿元。近5日资金流向一览见下表:信立泰融资融券信息显示,融资方面,当日融资买入2491.49万元,融资偿还2086.98万元,融资净买入404.5万元。融券方面,融券卖出3100.0股,融券偿还1.27万股,融券余量27.39万股,融券余额948.24万元。信立泰主营业务:药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120300009305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0196","BK0239","BK0028","BK0188","002294","BK0183"],"gpt_icon":0},{"id":"2486361333","title":"信立泰(002294.SZ):阿利沙坦酯氨氯地平片、苯甲酸福格列汀片新纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486361333","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486361333?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:01","pubTimestamp":1732780913,"startTime":"0","endTime":"0","summary":"智通财经APP讯,信立泰(002294.SZ)发布公告,根据国家医保局、人力资源社会保障部发布的《关于印发<国家基本医疗保险、工伤保险和生育保险药品目录(2024年)>的通知》(医保发〔2024〕33号),公司的创新药复立坦®(通用名:阿利沙坦酯氨氯地平片)、信立汀(通用名:苯甲酸福格列汀片),通过谈判新纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》乙类范围。本次产品入选国家医保目录,充分体现了国家对临床价值高、价格合理的创新药品的支持和认可。随着谈判药品进院工作的推进和“双通道”管理机制的完善,将更有利于市场推广和销售,为未来公司营收和利润做出贡献。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002294","BK0188","BK0183","BK0187","BK0196","BK0239","BK0028"],"gpt_icon":0},{"id":"2486438848","title":"信立泰11月27日现1笔大宗交易 成交金额365.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486438848","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486438848?lang=zh_cn&edition=full","pubTime":"2024-11-27 17:00","pubTimestamp":1732698000,"startTime":"0","endTime":"0","summary":" 11月27日,信立泰收涨3.01%,收盘价为34.24元,发生1笔大宗交易,合计成交量11万股,成交金额365.64万元。 进一步统计,近3个月内该股累计发生5笔大宗交易,合计成交金额为5.27亿元。该股近5个交易日累计上涨5.26%,主力资金合计净流入5462.15万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-27/doc-incxnwin3573258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002294","BK0196","BK0188","BK0028","BK0183","BK0239","BK0187"],"gpt_icon":0},{"id":"2486881095","title":"11月27日信立泰现365.64万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2486881095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486881095?lang=zh_cn&edition=full","pubTime":"2024-11-27 16:52","pubTimestamp":1732697574,"startTime":"0","endTime":"0","summary":"证券之星消息,11月27日信立泰发生大宗交易,交易数据如下:大宗交易成交价格33.24元,相对当日收盘价折价2.92%,成交11万股,成交金额365.64万元,买方营业部为南京证券股份有限公司南京柳洲南路证券营业部,卖方营业部为海通证券股份有限公司上海黄浦区福州路证券营业部。近三个月该股共发生5笔大宗交易,合计成交15.53万手,折价成交5笔。截至2024年11月27日收盘,信立泰报收于34.24元,上涨3.01%,换手率1.14%,成交量12.76万手,成交额4.34亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112700027292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0028","BK0188","002294","BK0239","BK0196"],"gpt_icon":0},{"id":"2486863072","title":"A股减肥药板块盘初活跃,昊帆生物涨超10%,诺泰生物、华森制药涨超4%,恒瑞医药、信立泰、百花医药等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2486863072","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486863072?lang=zh_cn&edition=full","pubTime":"2024-11-27 09:39","pubTimestamp":1732671569,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0187","002907","LU1064130708.USD","BK0028","BK0239","159982","600721","BK0012","BK0196","301393","BK0183","LU0405327148.USD","LU0405327494.USD","BK0188","002294","399300","600276","BK0229","BK0102","LU1328615791.USD","BK0216","LU2488822045.USD","LU1064131003.USD","BK0060","688076","LU2148510915.USD"],"gpt_icon":0},{"id":"2486868491","title":"信立泰(002294)11月26日主力资金净买入4423.40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486868491","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486868491?lang=zh_cn&edition=full","pubTime":"2024-11-27 09:12","pubTimestamp":1732669965,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月26日收盘,信立泰报收于33.24元,上涨4.3%,换手率1.17%,成交量13.06万手,成交额4.37亿元。近5日资金流向一览见下表:信立泰融资融券信息显示,融资方面,当日融资买入1648.92万元,融资偿还3432.63万元,融资净偿还1783.71万元。信立泰主营业务:药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112700008402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","BK0188","BK0187","BK0196","002294","BK0239"],"gpt_icon":0},{"id":"2486777448","title":"11月25日信立泰发生3笔大宗交易 成交金额1335.23万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486777448","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486777448?lang=zh_cn&edition=full","pubTime":"2024-11-25 16:48","pubTimestamp":1732524488,"startTime":"0","endTime":"0","summary":"证券之星消息,11月25日信立泰发生大宗交易,交易数据如下:近三个月该股共发生4笔大宗交易,合计成交15.42万手,折价成交4笔。该股近期无解禁股上市。截至2024年11月25日收盘,信立泰(002294)报收于31.87元,上涨0.44%,换手率0.64%,成交量7.18万手,成交额2.3亿元。该股最近90天内共有13家机构给出评级,买入评级10家,增持评级3家;过去90天内机构目标均价为39.51。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500021011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002294","BK0196","BK0183","BK0187","BK0028","BK0188"],"gpt_icon":0},{"id":"2485237897","title":"信立泰(002294.SZ)拟3000万元增资普瑞基准 提升研发效率","url":"https://stock-news.laohu8.com/highlight/detail?id=2485237897","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485237897?lang=zh_cn&edition=full","pubTime":"2024-11-22 18:03","pubTimestamp":1732269817,"startTime":"0","endTime":"0","summary":"智通财经APP讯,信立泰 公告,公司拟以自筹资金人民币3000万元增资参股公司普瑞基准科技(北京)有限公司,获得普瑞基准3.2154%股权。本次增资完成后,公司将直接持有普瑞基准8.5745%股权。公告显示,普瑞基准是一家为新药研发企业提供基于多组学数据挖掘的研发决策支持、中心实验室检测服务、转化医学服务公司,在多组学技术、生物信息学、生物统计/机器学习、中心实验室服务和伴随诊断开发方面具备独特技术。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002294","BK0196","BK0183","BK0187","BK0028","BK0188"],"gpt_icon":0},{"id":"2485467455","title":"信立泰:仿制药龙头押注创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485467455","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485467455?lang=zh_cn&edition=full","pubTime":"2024-11-21 19:37","pubTimestamp":1732189020,"startTime":"0","endTime":"0","summary":"多款创新产品上市信立泰营收过去主要依赖仿制药,但公司多年来积极布局创新转型,研发投入不断加大,同时重视研发团队建设。其中,苯甲酸福格列汀片和阿利沙坦酯氨氯地平片,分别是1类新药、2类新药,表明信立泰创新转型产出重要成果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2024-11-21/doc-incwvpzh4575306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002294","159992","BK0183","BK0187","06978","BK0196","BK0188","BK0239","BK1161","BK0028","BK1574"],"gpt_icon":0},{"id":"2484840521","title":"信立泰(002294)11月19日主力资金净卖出2318.94万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484840521","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484840521?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:21","pubTimestamp":1732065708,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月19日收盘,信立泰报收于30.18元,下跌0.63%,换手率0.95%,成交量10.53万手,成交额3.16亿元。近5日资金流向一览见下表:信立泰融资融券信息显示,融资方面,当日融资买入3176.96万元,融资偿还1362.11万元,融资净买入1814.85万元。信立泰主营业务:药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000009724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0196","BK0188","BK0183","BK0187","002294"],"gpt_icon":0},{"id":"2481693369","title":"信立泰(002294)11月5日主力资金净卖出1317.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481693369","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481693369?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:19","pubTimestamp":1730855988,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月5日收盘,信立泰报收于32.82元,下跌1.44%,换手率0.84%,成交量9.37万手,成交额3.09亿元。近5日资金流向一览见下表:信立泰融资融券信息显示,融资方面,当日融资买入3844.99万元,融资偿还2771.62万元,融资净买入1073.37万元。融券方面,融券卖出0.0股,融券偿还2.27万股,融券余量7.47万股,融券余额245.17万元。信立泰主营业务:药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600009061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0196","BK0188","BK0028","BK0183","BK0239","BK0187"],"gpt_icon":0},{"id":"2479279874","title":"信立泰:10月29日接受机构调研,交银基金、国泰君安等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479279874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479279874?lang=zh_cn&edition=full","pubTime":"2024-10-30 18:06","pubTimestamp":1730282778,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年10月30日信立泰发布公告称公司于2024年10月29日接受机构调研,交银基金徐嘉辰、国泰君安付子阳、东吴证券张坤 张翀翯 朱俊佳、富国基金王超 赵伟 曾新杰 孙笑悦 杨波参与。S086未来的市场竞争格局良好,获批后我们将争取医保准入。答:0108已申报上市,并提交发补,预计25年初获批。该股最近90天内共有12家机构给出评级,买入评级10家,增持评级2家;过去90天内机构目标均价为37.18。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000035852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","002294","BK0196","BK0188","BK0028","BK0183","BK0276","BK0239","BK0184","BK0187","02611","BK0201","601211","BK1147","BK1564"],"gpt_icon":0},{"id":"2477524821","title":"华安证券:给予信立泰买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2477524821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477524821?lang=zh_cn&edition=full","pubTime":"2024-10-24 13:45","pubTimestamp":1729748719,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超近期对信立泰进行研究并发布了研究报告《24Q3营收扣非超预期,恩那罗未来可期》,本报告对信立泰给出买入评级,当前股价为32.95元。我们看好公司创新转型带来的收入结构重塑,在心血管专科领域的深耕优势,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有12家机构给出评级,买入评级10家,增持评级2家;过去90天内机构目标均价为37.18。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400018214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","600909"],"gpt_icon":0},{"id":"2477511457","title":"信立泰(002294)10月23日主力资金净卖出1503.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477511457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477511457?lang=zh_cn&edition=full","pubTime":"2024-10-24 09:21","pubTimestamp":1729732918,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月23日收盘,信立泰报收于33.31元,下跌3.73%,换手率1.19%,成交量13.21万手,成交额4.44亿元。近5日资金流向一览见下表:信立泰融资融券信息显示,融资方面,当日融资买入5689.79万元,融资偿还3282.38万元,融资净买入2407.42万元,连续3日净买入累计7038.29万元。信立泰主营业务:药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400008311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","BK0188","BK0187","BK0196","002294","BK0028"],"gpt_icon":0},{"id":"2477324325","title":"华鑫证券:给予信立泰买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2477324325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477324325?lang=zh_cn&edition=full","pubTime":"2024-10-23 13:40","pubTimestamp":1729662029,"startTime":"0","endTime":"0","summary":"华鑫证券胡博新近期对信立泰进行研究并发布了研究报告《公司事件点评报告:持续加码研发,重磅品种稳步推进》,本报告对信立泰给出买入评级,当前股价为33.46元。创新药产品线持续丰富,收入占比稳步提升。最新盈利预测明细如下:该股最近90天内共有10家机构给出评级,买入评级8家,增持评级2家;过去90天内机构目标均价为37.18。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300018552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","161027"],"gpt_icon":0},{"id":"2477924183","title":"信立泰(002294)2024年三季报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2477924183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477924183?lang=zh_cn&edition=full","pubTime":"2024-10-23 06:04","pubTimestamp":1729634677,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期信立泰发布2024年三季报。根据财报显示,信立泰营收净利润同比双双增长。截至本报告期末,公司营业总收入30.01亿元,同比上升22.18%,归母净利润5.1亿元,同比上升6.37%。按单季度数据看,第三季度营业总收入9.58亿元,同比上升24.15%,第三季度归母净利润1.66亿元,同比上升17.01%。持有信立泰最多的基金为工银前沿医疗股票A,目前规模为97.86亿元,最新净值2.811,较上一交易日上涨0.32%,近一年下跌6.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300004659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"gpt_icon":0},{"id":"2477238808","title":"信立泰(002294)10月21日主力资金净卖出800.25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477238808","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477238808?lang=zh_cn&edition=full","pubTime":"2024-10-22 09:23","pubTimestamp":1729560232,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月21日收盘,信立泰报收于36.31元,下跌1.28%,换手率0.77%,成交量8.55万手,成交额3.09亿元。近5日资金流向一览见下表:信立泰融资融券信息显示,融资方面,当日融资买入3000.13万元,融资偿还1351.49万元,融资净买入1648.64万元。信立泰主营业务:药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200007462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0188","002294","BK0196","BK0183","BK0028","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","stockEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":0.0083},{"period":"3month","weight":0.035},{"period":"6month","weight":0.1975},{"period":"1year","weight":0.0599},{"period":"ytd","weight":0.0226}],"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","perCapita":"43046股","boardName":"医药制造业","registeredCapital":"111481万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":" 深圳信立泰药业股份有限公司主营业务是药品、医疗器械产品的研发、生产、销售。主要产品心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物等。","serverTime":1734962206475,"listedPrice":41.98,"stockholders":"25892人(较上一季度减少0.90%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}